Developments in Clinical Use of Plasma Therapies

Link to Website
BRUSSELS, BELGIUM (February 14th, 2012) The International Plasma Protein Congress (IPPC) 2012 will take place on March 13-14 in Madrid, Spain at the Hotel Melia Princesa and will feature a panel of experts discussing their findings on the development of clinical use of Plasma Protein Therapies .
Speakers will include Prof Günter AUERSWALD, Head of the Comprehensive Care Centre for Hemophilia and Thrombosis at the Professor Hess Children’s Hospital in Bremen, Germany; Dr Siraj MISBAH, consultant immunologist at the the John Radcliffe Hospital in Oxford, United Kingdom; Prof Matthias STURZENEGGER, Head of the Department of Neurology at the University Hospital of Bern, Switzerland and Dr Jacqueline KERR, senior clinical assessor at the Paul-Ehrlich-Institute, Germany . The session will be moderated by Dr Peter SPAETH, assistant professor at the Institute of Pharmacology of the University of Bern, Switzerland.
More on this session:
Prof Günter Auerswald will present on tolerisation as a route to prophylactic treatment of severe haemophilia.  Dr Auerswald’s research interests include von Willebrand’s disease, rare coagulation disorders and treatment protocols for hemophilia patients with inhibitors to factor VIII. He has published extensively on these subjects.
Dr Siraj Misbah will present clinical data for neurological immunomodulation. Dr. Misbah has extensive clinical experience of IVIg for both antibody replacement and immunomodulation. He has been actively involved in multi-centre randomised trials of IVIg in systemic vasculitis and the Lambert-Eaton syndrome. He has a particular interest in neuroimmunology.
Prof Matthias Sturzenegger will present his findings in the analysis of the role of IVIg in Chronic inflammatory polyneuropathy (CIDP) and other autoimmune neuropathies. Prof. Sturzenegger’s research interests include clinical neurology, non-atherosclerotic vasculopathies, cerebral hemodynamics, immunemediated neuropathies and whiplash associated disorders.
Dr Jacqueline Kerr  will present her view on the future of immunoglobulin use in the Alzheimer disease. Dr. Kerr is a certified psychiatrist and psychotherapist and holds a doctoral thesis in immunology. Her current work involves evaluations in European and national procedures covering all indications of immunoglobulins and the therapeutic use of monoclonal antibodies in a broad spectrum of disorders.
For more information, please visit the IPPC 2012 website, register and join us in Madrid.